J. Sastre

发表

Sorafenib for non-selected patient population with advanced hepatocellular carcinoma: efficacy and safety data according to liver function

J. Zugazagoitia, E. Díaz-Rubio, A. Manzano, 2013, Clinical and Translational Oncology.

Colon cancer molecular subtypes identified by expression profiling and associated to stroma, mucinous type and different clinical behavior

Javier Sastre, C. Fernández Pérez, T. Caldés, 2012, BMC Cancer.

Influence of KRAS p.G13D mutation in patients with metastatic colorectal cancer treated with cetuximab.

T. Caldés, E. Díaz-Rubio, J. Sastre, 2012, Clinical colorectal cancer.

Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial.

R. Greil, S. Kubicka, E. Van Cutsem, 2013, The Lancet. Oncology.

Clinical pattern and therapeutic results achieved in 1490 patients with germ-cell tumours of the testis: the experience of the Spanish Germ-Cell Cancer Group (GG).

M. Climent, L. Paz-Ares, J. Aparicio, 2002, European urology.

Circulating tumour cells in locally advanced breast cancer

M. L. Maestro, J. García-Saenz, Miguel Martín, 2009, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

A randomized phase II study of capecitabine-based chemoradiation with or without bevacizumab in resectable locally advanced rectal cancer: clinical and biological features

R. Salazar, C. Pericay, C. Grávalos, 2015, BMC Cancer.

SEOM-GEMCAD-TTD clinical guidelines for localized rectal cancer (2021)

M. Guillot, C. Pericay, J. Capdevila, 2022, Clinical and Translational Oncology.

Risk-adapted adjuvant chemotherapy after concomitant fluoropyrimidine-radiotherapy neoadjuvant treatment for patients with resectable cT3-4 or N+ rectal cancer

E. Díaz-Rubio, J. Sastre, J. Puente, 2011, Anti-cancer drugs.

Recommendations and expert opinion on the treatment of locally advanced rectal cancer in Spain

M. Salgado, C. Grávalos, J. Capdevila, 2011, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial.

Joon-Oh Park, M. Kudo, A. Zhu, 2015, The Lancet. Oncology.

Ramucirumab (RAM) as second-line treatment in patients (pts) with advanced hepatocellular carcinoma (HCC): Analysis of patients with elevated {alpha}-fetoprotein (AFP) from the randomized phase III REACH study.

Joon-Oh Park, M. Kudo, A. Zhu, 2015 .

First-line single-agent cetuximab in elderly patients with metastatic colorectal cancer. A phase II clinical and molecular study of the Spanish group for digestive tumor therapy (TTD).

A. Carrato, M. Hidalgo, M. Varella‐Garcia, 2011, Critical reviews in oncology/hematology.

A Polymorphism in the Cytidine Deaminase Promoter Predicts Severe Capecitabine-Induced Hand-Foot Syndrome

J. Benítez, A. González-Neira, G. Pita, 2011, Clinical Cancer Research.

Severe Capecitabine-Induced Hand-Foot Syndrome Promoter Predicts Cytidine Deaminase

J. Benítez, G. Pita, M. Alonso, 2011 .

Circulating tumoral cells lack circadian-rhythm in hospitalized metastasic breast cancer patients

M. Sanz-Casla, J. García-Saenz, Miguel Martín, 2006, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

Physician-perceived utility of the EORTC QLQ-GINET21 questionnaire in the treatment of patients with gastrointestinal neuroendocrine tumours: a multicentre, cross-sectional survey (QUALINETS)

Neus Canal, J. Capdevila, J. Gallego, 2021, Health and Quality of Life Outcomes.

SEOM-GEMCAD-TTD clinical guidelines for localized rectal cancer (2021)

M. Guillot, C. Pericay, J. Capdevila, 2022, Clinical and Translational Oncology.

Clinical management of regorafenib in the treatment of patients with advanced colorectal cancer

J. Feliu, C. Pericay, R. García-Carbonero, 2014, Clinical and Translational Oncology.

First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD study.

J. Tabernero, A. Abad, B. Massuti, 2012, The oncologist.

Phase III study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: final report of the Spanish Cooperative Group for the Treatment of Digestive Tumors Trial.

A. Carrato, J. Tabernero, A. Abad, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

First-line cetuximab plus capecitabine in elderly patients with advanced colorectal cancer: clinical outcome and subgroup analysis according to KRAS status from a Spanish TTD Group Study.

M. Hidalgo, B. Massuti, M. Valladares-Ayerbes, 2012, The oncologist.

Should capecitabine replace 5-fluorouracil in the first-line treatment of metastatic colorectal cancer?

E. Díaz-Rubio, J. Sastre, M. Sotelo, 2014, World journal of gastroenterology.

Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 study KRAS subgroup findings.

R. Greil, S. Kubicka, E. Van Cutsem, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Irinotecan in the treatment of elderly patients with advanced colorectal cancer.

J. García-Saenz, E. Díaz-Rubio, J. Sastre, 2008, Critical reviews in oncology/hematology.

A phase I, dose-finding study of irinotecan (CPT-11) short i.v. infusion combined with fixed dose of 5-fluorouracil (5-FU) protracted i.v. infusion in adult patients with advanced solid tumours

L. Paz-Ares, A. Carcas, J. Frías, 2005, Cancer Chemotherapy and Pharmacology.

First-line single-agent panitumumab in frail elderly patients with wild-type KRAS metastatic colorectal cancer and poor prognostic factors: A phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumours.

B. Massuti, F. Rivera, C. Grávalos, 2015, European journal of cancer.

Role of circulating tumor cells as prognostic marker in resected stage III colorectal cancer.

C. Pericay, C. Grávalos, E. Díaz-Rubio, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Induction chemotherapy with cisplatin/docetaxel versus cisplatin/5-fluorouracil for locally advanced squamous cell carcinoma of the head and neck: a randomised phase II study.

J. Tisaire, J. Sastre, A. Rueda, 2005, European journal of cancer.

Prognostic significance of tumor regression in lymph nodes after neoadjuvant therapy for rectal carcinoma

M. Fernández-Aceñero, J. Sastre, B. García-Paredes, 2016, Virchows Archiv.

UFT in combination with oxaliplatin: clinical phase I study in patients with advanced or metastatic solid tumors

A. Carrato, A. Abad, E. Díaz-Rubio, 2006, Anti-cancer drugs.

5-Fluorouracil as a protracted continuous infusion plus irinotecan (CPT-11) in patients with advanced colorectal cancer treated with fluoropyrimidine-based regimens as first line

E. Díaz-Rubio, J. Sastre, R. Alfonso, 2003, Anti-cancer drugs.

Cetuximab plus oxaliplatin/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFOX-4) for the epidermal growth factor receptor (EGFR)expressing metastatic colorectal cancer (mCRC) in the first-line setting: a phase II study

Y. Humblet, A. Zubel, A. Gramont, 2005 .

An international phase II study of cetuximab in combination with oxaliplatin/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFOX-4) in the first-line treatment of patients with metastatic colorectal cancer (CRC) expressing Epidermal Growth Factor Receptor (EGFR). Preliminary results.

E. Van Cutsem, J. Tabernero, Y. Humblet, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Single‐Agent Regorafenib in Metastatic Colorectal Cancer Patients with Any RAS or BRAF Mutation Previously Treated with FOLFOXIRI plus Bevacizumab (PREVIUM Trial)

C. Montagut, F. Rivera, M. Salgado, 2018, The oncologist.

Influence of BRAF and PIK3CA mutations on the efficacy of FOLFIRI plus bevacizumab or cetuximab as first-line therapy in patients with RAS wild-type metastatic colorectal carcinoma and <3 baseline circulating tumour cells: the randomised phase II VISNÚ-2 study

E. Polo, M. Guillot, M. Valladares-Ayerbes, 2021, ESMO open.

Association Between Baseline Circulating Tumor Cells, Molecular Tumor Profiling, and Clinical Characteristics in a Large Cohort of Chemo-naïve Metastatic Colorectal Cancer Patients Prospectively Collected.

B. Bellosillo, M. Balbín, E. Díaz-Rubio, 2020, Clinical colorectal cancer.

Chemotherapy for gastric cancer.

J. García-Saenz, E. Díaz-Rubio, J. Sastre, 2006, World journal of gastroenterology.

SEOM clinical guideline for the diagnosis and treatment of gastric cancer (GC) and gastroesophageal junction adenocarcinoma (GEJA) (2019)

M. Alsina, F. Rivera, P. Jiménez-Fonseca, 2020, Clinical and Translational Oncology.

Recommendations on current approach to gastric cancer

A. Carrato, F. Rivera, C. Pericay, 2009, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

Successful rectal cancer local recurrence radiofrequency ablation

J. Mayol, J. García-Saenz, E. Díaz-Rubio, 2008, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

C8-T1 Radiculopathy Due to an Intradural Extramedullary Metastasis of a Pancreatic Neuroendocrine Tumor: Case Report and Review of the Literature.

E. Díaz-Rubio, J. Sastre, S. Cabezas-Camarero, 2016, Pancreas.

Circulating tumor cells following first chemotherapy cycle: an early and strong predictor of outcome in patients with metastatic breast cancer.

J. García-Saenz, Miguel Martín, E. Díaz-Rubio, 2013, The oncologist.

Antiproliferative effects of lanreotide autogel in patients with progressive, well-differentiated neuroendocrine tumours: a Spanish, multicentre, open-label, single arm phase II study

B. Massuti, D. Castellano, F. Rivera, 2013, BMC Cancer.

Circulating tumor cell count is a prognostic factor in metastatic colorectal cancer patients receiving first-line chemotherapy plus bevacizumab: a Spanish Cooperative Group for the Treatment of Digestive Tumors study.

J. Tabernero, A. Abad, B. Massuti, 2012, The oncologist.

First-Line Biological Agents Plus Chemotherapy in Older Patients with Metastatic Colorectal Cancer: A Retrospective Pooled Analysis

A. Carrato, R. Salazar, C. García-Girón, 2021, Drugs & Aging.

Cuirasse skin metastases secondary to gastric adenocarcinoma

E. Díaz-Rubio, J. Sastre, J. L. López García-Asenjo, 2005, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

Tumour location and efficacy of first-line EGFR inhibitors in KRAS/RAS wild-type metastatic colorectal cancer: retrospective analyses of two phase II randomised Spanish TTD trials

A. Carrato, A. Abad, B. Massuti, 2019, ESMO Open.

Upfront primary tumour resection and survival in synchronous metastatic colorectal cancer according to primary tumour location and RAS status: Pooled analysis of the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD).

A. Carrato, A. Abad, C. Montagut, 2021, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Treatment and outcome of patients with stage IS testicular cancer: A retrospective study from the Spanish Germ Cell Cancer Group.

S. Ochenduszko, J. Aparicio, I. Durán, 2019, The Journal of urology.

Chemotherapy as an alternative to radiotherapy in the treatment of stage IIA and IIB testicular seminoma: a Spanish Germ Cell Cancer Group Study.

J. Aparicio, P. Maroto, J. Germá-Lluch, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Glutathione S-transferases μ1, θ1, π1, α1 and μ3 genetic polymorphisms and the risk of colorectal and gastric cancers in humans

M. Díaz‐Rubio, E. García-Martín, J. Agúndez, 2006 .

Circulating tumor cells in metastatic breast cancer: timing of blood extraction for analysis.

J. García-Saenz, Miguel Martín, E. Díaz-Rubio, 2009, Anticancer research.

Circulating tumor cells in solid tumor in metastatic and localized stages.

J. García-Saenz, Miguel Martín, E. Díaz-Rubio, 2009, Anticancer research.

Vanishing biodiversity.

G. Gervasini, M. Díaz‐Rubio, E. García-Martín, 1996, BMC Cancer.

sVEGFR2 and circulating tumor cells to predict for the efficacy of pazopanib in neuroendocrine tumors (NETs): PAZONET subgroup analysis.

J. García-Donas, I. Durán, D. Castellano, 2013 .

LBA16RAMUCIRUMAB (RAM) AS SECOND-LINE TREATMENT IN PATIENTS (PTS) WITH ADVANCED HEPATOCELLULAR CARCINOMA (HCC) FOLLOWING FIRST-LINE THERAPY WITH SORAFENIB: RESULTS FROM THE RANDOMIZED PHASE III REACH STUDY

M. Kudo, A. Zhu, C. Yen, 2014 .

Patterns of practice of regional nodal irradiation in breast cancer: results of the European Organization for Research and Treatment of Cancer (EORTC) NOdal Radiotherapy (NORA) survey †

C. Pericay, C. Grávalos, E. Díaz-Rubio, 2015 .

Genotype-based selection of treatment of patients with advanced colorectal cancer (SETICC): a pharmacogenetic-based randomized phase II trial

A. Carrato, R. Salazar, A. Abad, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase II trial of panitumumab plus FOLFOX4 or FOLFIRI in subjects with KRAS wild-type colorectal cancer and liver-limited disease: The PLANET study.

A. Carrato, A. Abad, B. Massuti, 2014 .

Pharmacogenetic approach for capecitabine or 5-fluorouracil selection to be combined with oxaliplatin as first-line chemotherapy in advanced colorectal cancer.

E. Guinó, A. Abad, J. Aparicio, 2008, European journal of cancer.

Correlation between HER2/neu overexpression/amplification and clinicopathologic parameters in advanced gastric cancer (AGC) patients (pts): A prospective study.

A. Jimeno, F. Rivera, R. García-Carbonero, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic value of the combination of circulating tumor cells plus KRAS in patients with metastatic colorectal cancer treated with chemotherapy plus bevacizumab.

A. Abad, B. Massuti, F. Rivera, 2013, Clinical colorectal cancer.

Circulating tumor cells in colorectal cancer: correlation with clinical and pathological variables.

M. Sanz-Casla, J. García-Saenz, E. Díaz-Rubio, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase II/III trial of induction chemotherapy (ICT) with cisplatin/5-fluorouracil (PF) vs. docetaxel (T) plus PF (TPF) followed by chemoradiotherapy (CRT) vs. CRT for unresectable locally advanced head and neck cancer (LAHNC)

J. Carles, R. Hitt, H. Cortés-Funes, 2005 .

Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study.

Edward J. Kim, P. Philip, J. Lacy, 2020, The lancet. Gastroenterology & hepatology.

BEVACIZUMAB (BEV) plus CHEMOTHERAPY (CT) BEYOND FIRST PROGRESSION IN PATIENTS (PTS) WITH METASTATIC COLORECTAL CANCER (MCRC) PREVIOUSLY TREATED WITH FIRST-LINE BEV plus CT (ML18147): EFFICACY AND SAFETY ANALYSES BY OXALIPLATIN VS IRINOTECAN-BASED CT

R. Greil, S. Kubicka, T. André, 2012 .

Bevacizumab (BEV) continued beyond first progression in patients (pts) with metastatic colorectal cancer (mCRC) previously treated with BEV + chemotherapy (CT): Biomarker findings from ML18147.

R. Greil, S. Kubicka, T. Mueller, 2013 .

Efficacy and Safety of Treatment with Bevacizumab (BEV) + Chemotherapy (CT) Beyond First Progression in Patients (PTS) with Metastatic Colorectal Cancer (MCRC) Previously Treated with BEV + CT: Age Subgroup Analysis From a Randomised Phase III Intergroup Study (ML18147)

O. Bouché, D. Arnold, T. André, 2012 .

Analysis of potential predictive factors of clinical benefit in patients (pts) with metastatic colorectal cancer (MCRC) treated with single-agent cetuximab as first-line treatment

A. Jimeno, M. Hidalgo, M. Varella‐Garcia, 2007 .

Prognostic factors for relapse in stage I seminoma: a new nomogram derived from three consecutive, risk-adapted studies from the Spanish Germ Cell Cancer Group (SGCCG).

J. Carles, M. Margelí, J. Aparicio, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Risk-adapted treatment in clinical stage I testicular seminoma: the third Spanish Germ Cell Cancer Group study.

X. G. Del Muro, M. Margelí, J. Aparicio, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Neuroendocrine Neoplasms in Rare Locations: Clinicopathological Features and Review of the Literature

J. Sastre, M. J. Fernández Aceñero, Cristina Díaz del Arco, 2018, Indian journal of endocrinology and metabolism.

Association of miR-21 and miR-335 to microsatellite instability and prognosis in stage III colorectal cancer.

B. Perez-Villamil, E. Díaz-Rubio, E. Aranda, 2021, Cancer biomarkers : section A of Disease markers.

Results of REARRANGE trial: A randomized phase 2 study comparing different dosing approaches for regorafenib (REG) during the first cycle of treatment in patients (pts) with metastatic colorectal cancer (mCRC).

J. Tabernero, F. Ciardiello, M. Valladares-Ayerbes, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

The status of PD-L1 and tumor-in ﬁ ltrating immune cells predict resistance and poor prognosis in BRAFi-treated melanoma patients harboring mutant BRAF V600

A. Carrato, C. Rodríguez-Antona, J. García-Donas, 2015 .

Randomized phase III trial of the TTD Group comparing capecitabine and oxaliplatin (XELOX) vs. oxaliplatin and 5-fluorouracil in continuous infusion (FUFOX) as first line treatment in advanced or metastatic colorectal cancer (CRC).

A. Carrato, J. Tabernero, A. Abad, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

N-acetyltransferase 2 (NAT2) genotype and colorectal carcinoma: risk variability according to tumour site?

M. Díaz‐Rubio, J. Benítez, J. Sastre, 2000, Scandinavian journal of gastroenterology.

Postchemotherapy resections of residual masses from metastatic nonseminomatous testicular germ cell tumors. A Spanish Germ Cell Group study

L. Paz-Ares, J. Aparicio, E. Alba, 2005 .

A randomised phase 2 study comparing different dose approaches of induction treatment of regorafenib in previously treated metastatic colorectal cancer patients (REARRANGE trial).

Cristina Santos, R. Goldberg, J. Tabernero, 2022, European journal of cancer.

Continuous infusion 5-Fluorouracil with or without cisplatin for the treatment of advanced gastric cancer. Results of two consecutive phase II trials of the Spanish Group for Gastrointestinal Tumor Therapy (TTD)

A. Carrato, J. Aparicio, A. Antón, 1999 .

Molecular Classification of Colorectal Cancer by microRNA Profiling: Correlation with the Consensus Molecular Subtypes (CMS) and Validation of miR-30b Targets

A. Pascual-Montano, B. Perez-Villamil, D. Tabas-Madrid, 2022, Cancers.

Molecular characterization of HER2-positive (HER2+) metastatic gastric and gastro-esophageal junction cancer patients (mGC): Identification of resistance mechanisms to trastuzumab-based therapy (TTZ)

P. Nuciforo, J. Tabernero, A. Pandiella, 2016 .

Phase I dose finding study of irinotecan (CPT-11) over a short i.v. infusion combined with a fixed dose of 5-fluorouracil (5-FU) protracted continuous i.v. infusion in patients with advanced solid tumours

P. Hérait, L. Paz-Ares, A. Carcas, 1997 .

Ramucirumab as Second-Line Treatment in Patients with Advanced Hepatocellular Carcinoma: Analysis of Reach Patients by Albumin-Bilirubin (ALBI) Grade

M. Kudo, A. Zhu, C. Yen, 2016 .

Re: Mette Saksø Mortensen, Jakob Lauritsen, Maria Gry Gundgaard, et al. A nationwide cohort study of stage I seminoma patients followed on a surveillance program. Eur Urol 2014;66:1172-8.

J. Aparicio, P. Maroto, J. Sastre, 2015, European urology.

Study of KRAS new predictive marker in a clinical laboratory

T. Caldés, M. Ferrer, J. Sastre, 2012, Clinical and Translational Oncology.

Cost-utility analysis of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) in combination with gemcitabine in metastatic pancreatic cancer in Spain: results of the PANCOSTABRAX study

A. Carrato, F. Rivera, R. López, 2015, Expert review of pharmacoeconomics & outcomes research.

[Diagnosis and treatment of hepatocellular carcinoma. Update consensus document from the AEEH, SEOM, SERAM, SERVEI and SETH].

J. Bruix, J. Llovet, A. Forner, 2016, Medicina clinica.

Phase II trial of miniDOX (reduced dose docetaxel–oxaliplatin–capecitabine) in “suboptimal” patients with advanced gastric cancer (AGC). TTD 08-02

M. Alsina, B. Massuti, M. Valladares-Ayerbes, 2013, Cancer Chemotherapy and Pharmacology.

Phase II study of necitumumab plus modified FOLFOX6 as first-line treatment in patients with locally advanced or metastatic colorectal cancer

A. Cervantes, T. Delaunoit, J. Wallin, 2016, British Journal of Cancer.

Whole exome sequencing identifies PLEC, EXO5 and DNAH7 as novel susceptibility genes in testicular cancer

M. Urioste, J. Benítez, C. López, 2018, International journal of cancer.

nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial.

W. Scheithauer, J. Tabernero, V. Heinemann, 2015, Journal of the National Cancer Institute.

Phase 1b Dose Escalation Study of Erlotinib in Combination with Infusional 5-Fluorouracil, Leucovorin, and Oxaliplatin in Patients with Advanced Solid Tumors

J. Cassidy, Robert J. Jones, E. Díaz-Rubio, 2007, Clinical Cancer Research.

Sorafenib and bevacizumab combination targeted therapy in advanced neuroendocrine tumour: a phase II study of Spanish Neuroendocrine Tumour Group (GETNE0801).

R. Salazar, I. Durán, D. Castellano, 2013, European journal of cancer.

Hepatocellular and biliary tract carcinomas: SEOM clinical guidelines

J. Feliu, J. Maurel, D. Isla, 2011, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

Prognostic Value of BRAF, PI3K, PTEN, EGFR Copy Number, Amphiregulin and Epiregulin Status in Patients with KRAS Codon 12 Wild-Type Metastatic Colorectal Cancer Receiving First-Line Chemotherapy with Anti-EGFR Therapy

A. Carrato, J. Feliu, C. Grávalos, 2015, Molecular Diagnosis & Therapy.

Role of cetuximab in first-line treatment of metastatic colorectal cancer.

E. Díaz-Rubio, J. Sastre, M. Sotelo, 2014, World journal of gastroenterology.

Role of Kras Status in Patients with Metastatic Colorectal Cancer Receiving First-Line Chemotherapy plus Bevacizumab: A TTD Group Cooperative Study

A. Carrato, J. Tabernero, J. García-Foncillas, 2012, PloS one.

Biomarkers and anti-EGFR therapies for KRAS wild-type metastatic colorectal cancer

J. García-Saenz, J. Sastre, E. Díaz-Rubio García, 2009, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

Multicenter study evaluating a dual policy of postorchiectomy surveillance and selective adjuvant single-agent carboplatin for patients with clinical stage I seminoma.

J. Carles, L. Paz-Ares, J. Aparicio, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

FOLFOXIRI plus bevacizumab versus FOLFOX plus bevacizumab for patients with metastatic colorectal cancer and ≥3 circulating tumour cells: the randomised phase III VISNÚ-1 trial

F. Rivera, R. García-Carbonero, E. Díaz-Rubio, 2020, ESMO Open.

Management and supportive treatment of frail patients with metastatic pancreatic cancer.

A. Carrato, M. Hidalgo, T. Macarulla, 2019, Journal of geriatric oncology.

Genetic and epigenetic profile of sporadic pheochromocytomas

M. Fraga, J. Benítez, M. Esteller, 2004, Journal of Medical Genetics.

Consensus on the treatment of pancreatic cancer in Spain

M. Hidalgo, J. Tabernero, A. Abad, 2009, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

Significance of the immunohistochemical detection of lymph node micrometastases in Stage II Colorectal Carcinoma

P. Pérez-Segura, J. García-Saenz, E. Díaz-Rubio, 2006, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

Pazopanib in pretreated advanced neuroendocrine tumors: a phase II, open-label trial of the Spanish Task Force Group for Neuroendocrine Tumors (GETNE).

A. Carrato, C. Rodríguez-Antona, J. García-Donas, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Consensus Recommendations from the Spanish Germ Cell Cancer Group on the Use of High-dose Chemotherapy in Germ Cell Cancer.

T. Powles, E. Esteban, X. G. Del Muro, 2017, European urology focus.

Phase II of trastuzumab and cisplatin in patients (pts) with advanced gastric cancer (AGC) with HER2/neu overexpression/amplification

F. Rivera, R. García-Carbonero, C. Grávalos, 2007 .

Synchronous versus metachronous brain metastasis from testicular germ cell tumors (TGCT): an analysis from the Spanish Germ Cell Cancer Group data base

E. Gallardo, J. Maroto, J. Aparicio, 2014, Clinical and Translational Oncology.

Intravenous and Oral Magnesium Supplementations in the Prophylaxis of Cisplatin‐Induced Hypomagnesemia

E. Díaz-Rubio, A. Casado, J. Sastre, 1992, American journal of clinical oncology.

Phase II study of trastuzumab and cisplatin as first-line therapy in patients with HER2-positive advanced gastric or gastroesophageal junction cancer

A. Jimeno, F. Rivera, R. García-Carbonero, 2011, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

The role of PIGF blockade in the treatment of colorectal cancer: overcoming the pitfalls

J. Tabernero, C. Montagut, T. Macarulla, 2020, Expert opinion on biological therapy.

Association of CYP2C9 genotypes leading to high enzyme activity and colorectal cancer risk.

M. Díaz‐Rubio, E. García-Martín, J. Agúndez, 2002, Carcinogenesis.

A phase II, open label study to evaluate the relationship between skin rash and survival in patients with unresectable and/or metastatic pancreatic cancer treated with erlotinib combined with gemcitabine.

F. Rivera, C. Pericay, A. Irigoyen, 2010 .

Practical prognostic index for patients with metastatic recurrent breast cancer: retrospective analysis of 2,322 patients from the GEICAM Spanish El Alamo Register

A. Ruíz, A. Lluch, E. Alba, 2010, Breast Cancer Research and Treatment.

Treatment of colorectal cancer in older patients: International Society of Geriatric Oncology (SIOG) consensus recommendations 2013.

D. Sargent, E. Van Cutsem, M. Aapro, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Prognostic Significance of Venous Thromboembolic Events in Disseminated Germ Cell Cancer Patients

B. Mellado, M. Margelí, C. Valverde, 2017, Journal of the National Cancer Institute.

Bevacizumab (BEV) plus chemotherapy (CT) continued beyond first progression in patients with metastatic colorectal cancer (mCRC) previously treated with BEV plus CT: Results of a randomized phase III intergroup study (TML study).

R. Greil, S. Kubicka, E. Van Cutsem, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Elderly patients with advanced colorectal cancer derive similar benefit without excessive toxicity after first-line chemotherapy with oxaliplatin-based combinations: comparative outcomes from the 03-TTD-01 phase III study.

A. Carrato, J. Tabernero, A. Abad, 2009, Critical reviews in oncology/hematology.

Irinotecan in combination with fluorouracil in a 48-hour continuous infusion as first-line chemotherapy for elderly patients with metastatic colorectal cancer: a Spanish Cooperative Group for the Treatment of Digestive Tumors study.

A. Carrato, A. Abad, J. Maurel, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Two consecutive studies using oral UFT-based chemotherapy regimens in elderly patients with advanced colorectal cancer

A. Carrato, A. Abad, M. Guillot, 2000, Revista de Oncología.

SEOM clinical guidelines for diagnosis and treatment of testicular seminoma (2010)

J. Aparicio, D. Isla, J. Sastre, 2011, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

Antiproliferative effects of lanreotide autogel in patients with progressive, well-differentiated neuroendocrine tumours: a Spanish, multicentre, open-label, single arm phase II study

B. Massuti, D. Castellano, F. Rivera, 2013, BMC Cancer.

A. Carrato, J. Feliu, C. Grávalos, 2015, Molecular Diagnosis & Therapy.

Second-line therapy for advanced pancreatic cancer: a review of the literature and future directions.

E. Díaz-Rubio, J. Sastre, J. Puente, 2009, Cancer treatment reviews.

Targeted Therapies in Older Patients with Metastatic Colorectal Cancer

J. Zugazagoitia, E. Díaz-Rubio, A. Manzano, 2013 .

UFT Plus Oral Folinic Acid as Therapy for Metastatic Colorectal Cancer in Older Patients

A. Abad, Cristina Martín, E. Díaz-Rubio, 1997 .

SEOM guidelines: non-seminomatous germ cell cancer (NSGCC)

P. Maroto, D. Isla, J. Sastre, 2011, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

A randomized, placebo-controlled phase 2 study of ganitumab or conatumumab in combination with FOLFIRI for second-line treatment of mutant KRAS metastatic colorectal cancer.

R. Loberg, J. Tabernero, S. Choo, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

First-line mFOLFOX plus cetuximab followed by mFOLFOX plus cetuximab or single-agent cetuximab as maintenance therapy in patients with metastatic colorectal cancer: Phase II randomised MACRO2 TTD study.

F. Rivera, R. López, C. Grávalos, 2018, European journal of cancer.

Two consecutive phase II trials of biweekly oxaliplatin plus weekly 48-hour continuous infusion of nonmodulated high-dose 5-fluorouracil as first-line treatment for advanced colorectal cancer.

A. Carrato, A. Abad, A. Antón, 2005, Clinical colorectal cancer.

Interim results of a multicenter phase II trial of nab-paclitaxel (nab-P) plus gemcitabine (G) for patients (Pts) with locally advanced pancreatic cancer (LAPC).

Edward J. Kim, P. Philip, J. Lacy, 2017 .

[Diagnosis and treatment of hepatocellular carcinoma].

M. Buti, J. Bruix, J. Llovet, 2009, Medicina clinica.

Pazonet: A Phase II Trial of Pazopanib as a Sequencing Treatment in Progressive Metastatic Neuroendocrine Tumors (NETS) Patients (PTS), On Behalf of The Spanish Task Force for Nets (GETNE)

A. Carrato, R. Salazar, I. Durán, 2012 .

Phase I/II Trial to Evaluate the Efficacy and Safety of Nanoparticle Albumin-Bound Paclitaxel in Combination With Gemcitabine in Patients With Pancreatic Cancer and an ECOG Performance Status of 2.

M. Hidalgo, F. Rivera, A. M. Muñoz Martín, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Colon cancer molecular subtypes identified by expression profiling and associatedto stroma, mucinous type and different clinical behavior

C. Fernández Pérez, T. Caldés, A. Calles, 2012, BMC Cancer.

Risk-Adapted Adjuvant Chemotherapy After Concomitant Fluoropyrimidine-Radiotherapy Neoadjuvant Treatment for Patients With Resectable CT3-4 or N+ Rectal Cancer: Five-Year Disease-Free Survival Results of a Single-Center Series.

C. Fernández, E. Díaz-Rubio, J. Sastre, 2016, Clinical colorectal cancer.

Abstract 2610: TYMS and XRCC1 gene polymorphisms as possible predictors for the addition of oxaliplatin to 5FU in the adjuvant treatment of stage II and III colorectal cancer

R. Salazar, A. Abad, F. Rivera, 2010 .

Sorafenib and bevacizumab combination targeted therapy in advanced neuroendocrine tumor: A phase II study of the Spanish Neuroendocrine Tumor Group (GETNE0801).

R. Salazar, A. Abad, I. Durán, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Updated survival from a randomized phase III trial (MPACT) of nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients (pts) with metastatic adenocarcinoma of the pancreas.

W. Scheithauer, J. Tabernero, V. Heinemann, 2014 .

Comparison of Two EpCAM-Based Methods for CTC Detection and Molecular Characterization in Advanced Colorectal Cancer

M. Provencio, E. Díaz-Rubio, E. Aranda, 2016 .

Clinical guideline SEOM: hepatocellular carcinoma

J. García-Foncillas, J. Feliu, M. Salgado, 2015, Clinical and Translational Oncology.

Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines.

M. Ychou, A. Abad, M. Marty, 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

A randomized phase III trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer.

C. García-Girón, R. Hitt, C. Jara-Sánchez, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Oxaliplatin as single agent in previously untreated colorectal carcinoma patients: a phase II multicentric study.

R. Labianca, C. Boni, A. Zaniboni, 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

SEOM clinical guidelines for diagnosis and treatment of metastatic colorectal cancer (2018)

J. Aparicio, J. Feliu, D. Páez, 2018, Clinical and Translational Oncology.

Neuroendocrine tumors and CUP

A. Carrato, M. Kudo, R. Salazar, 2012 .

Randomized phase III study comparing FOLFOX + bevacizumab versus folfoxiri + bevacizumab (BEV) as 1st line treatment in patients with metastatic colorectal cancer (mCRC) with ≥3 baseline circulating tumor cells (bCTCs).

R. López, R. García-Carbonero, E. Díaz-Rubio, 2019, Journal of Clinical Oncology.

Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with weekly high-dose 48-hour continuous-infusion fluorouracil for advanced colorectal cancer: a Spanish Cooperative Group for Gastrointestinal Tumor Therapy (TTD) study.

A. Carrato, J. Garcia-conde, A. Tres, 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

Association of Circulating Tumor Cells and Tumor Molecular Profile With Clinical Outcomes in Patients With Previously Untreated Metastatic Colorectal Cancer: A Pooled Analysis of the Phase III VISNÚ-1 and Phase II VISNÚ-2 Randomized Trials.

M. Guillot, M. Valladares-Ayerbes, F. Rivera, 2023, Clinical colorectal cancer.

First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD study.

J. Tabernero, A. Abad, F. Rivera, 2012, The oncologist.

Effectiveness and safety of aflibercept for metastatic colorectal cancer: retrospective review within an early access program in Spain

J. Feliu, M. Valladares-Ayerbes, R. Vera, 2017, Clinical and Translational Oncology.

R. Greil, S. Kubicka, M. Makrutzki, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.